Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Down-regulation of inwardly rectifying Kir2.1 K+ channels by human parvovirus B19 capsid protein VP1.
Ahmed M
,
Elvira B
,
Almilaji A
,
Bock CT
,
Kandolf R
,
Lang F
.
???displayArticle.abstract???
Parvovirus B19 (B19V) has previously been shown to cause endothelial dysfunction. B19V capsid protein VP1 harbors a lysophosphatidylcholine producing phospholipase A2 (PLA2). Lysophosphatidylcholine inhibits Na(+)/K(+) ATPase, which in turn may impact on the activity of inwardly rectifying K(+) channels. The present study explored whether VP1 modifies the activity of Kir2.1 K(+) channels. cRNA encoding Kir2.1 was injected into Xenopus oocytes without or with cRNA encoding VP1 isolated from a patient suffering from fatal B19V-induced inflammatory cardiomyopathy or the VP1 mutant (H153A)VP1 lacking a functional PLA2 activity. K(+) channel activity was determined by dual electrode voltage clamp. In addition, Na(+)/K(+)-ATPase activity was estimated from K(+)-induced pump current (I(pump)) and ouabain-inhibited current (I(ouabain)). Injection of cRNA encoding Kir2.1 into Xenopus oocytes was followed by appearance of inwardly rectifying K(+) channel activity (I(K)), which was significantly decreased by additional injection of cRNA encoding VP1, but not by additional injection of cRNA encoding (H153A)VP1. The effect of VP1 on I K was mimicked by lysophosphatidylcholine (1 μg/ml) and by inhibition of Na(+)/K(+)-ATPase with 0.1 mM ouabain. In the presence of lysophosphatidylcholine, I K was not further decreased by additional treatment with ouabain. The B19V capsid protein VP1 thus inhibits Kir2.1 channels, an effect at least partially due to PLA2-dependent formation of lysophosphatidylcholine with subsequent inhibition of Na(+)/K(+)-ATPase activity.
Ahmed,
Down-regulation of K⁺ channels by human parvovirus B19 capsid protein VP1.
2014, Pubmed,
Xenbase
Ahmed,
Down-regulation of K⁺ channels by human parvovirus B19 capsid protein VP1.
2014,
Pubmed
,
Xenbase
Alesutan,
Upregulation of Na-coupled glucose transporter SGLT1 by Tau tubulin kinase 2.
2012,
Pubmed
,
Xenbase
Almilaji,
Down-regulation of Na/K+ atpase activity by human parvovirus B19 capsid protein VP1.
2013,
Pubmed
,
Xenbase
Almilaji,
Upregulation of Na+,Cl(-)-coupled betaine/γ-amino-butyric acid transporter BGT1 by Tau tubulin kinase 2.
2013,
Pubmed
,
Xenbase
Anderson,
Human parvovirus, the cause of erythema infectiosum (fifth disease)?
1983,
Pubmed
Bock,
Human parvovirus B19-associated myocarditis.
2010,
Pubmed
Bogatikov,
Up-regulation of amino acid transporter SLC6A19 activity and surface protein abundance by PKB/Akt and PIKfyve.
2012,
Pubmed
,
Xenbase
Brown,
Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen).
1994,
Pubmed
Brown,
Molecular, cellular and clinical aspects of parvovirus B19 infection.
1994,
Pubmed
Brown,
What threat is human parvovirus B19 to the fetus? A review.
1989,
Pubmed
Brown,
Erythrocyte P antigen: cellular receptor for B19 parvovirus.
1993,
Pubmed
Bültmann,
Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease.
2003,
Pubmed
Canaan,
Interfacial enzymology of parvovirus phospholipases A2.
2004,
Pubmed
Corman,
Polyarteritis nodosa and parvovirus B19 infection.
1992,
Pubmed
Cotmore,
Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments.
1986,
Pubmed
Crane,
Parvovirus B19 infection in pregnancy.
2002,
Pubmed
Dingli,
Severe digital arterial occlusive disease and acute parvovirus B19 infection.
2000,
Pubmed
Doerig,
A transcriptional promoter of the human parvovirus B19 active in vitro and in vivo.
1987,
Pubmed
Dorsch,
The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity.
2002,
Pubmed
Drago,
Parvovirus B19 infection associated with acute hepatitis and a purpuric exanthem.
1999,
Pubmed
Duechting,
Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells.
2008,
Pubmed
Ellis,
Adhesion of endothelial cells to NOV is mediated by the integrins alphavbeta3 and alpha5beta1.
2003,
Pubmed
Finkel,
Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent?
1994,
Pubmed
Gigler,
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins.
1999,
Pubmed
Heegaard,
Human parvovirus B19.
2002,
Pubmed
Henrion,
Overlapping cardiac phenotype associated with a familial mutation in the voltage sensor of the KCNQ1 channel.
2012,
Pubmed
,
Xenbase
Hillingsø,
Parvovirus B19 and acute hepatitis in adults.
1998,
Pubmed
Hosseinzadeh,
Upregulation of peptide transporters PEPT1 and PEPT2 by Janus kinase JAK2.
2013,
Pubmed
,
Xenbase
Hosseinzadeh,
Down-regulation of the epithelial Na⁺ channel ENaC by Janus kinase 2.
2014,
Pubmed
,
Xenbase
Hosseinzadeh,
Downregulation of ClC-2 by JAK2.
2012,
Pubmed
,
Xenbase
Hosseinzadeh,
Down-regulation of the myoinositol transporter SMIT by JAK2.
2012,
Pubmed
,
Xenbase
Hsu,
Human parvovirus B19 non-structural protein (NS1) induces apoptosis through mitochondria cell death pathway in COS-7 cells.
2004,
Pubmed
Karetnyi,
Human parvovirus B19 infection in acute fulminant liver failure.
1999,
Pubmed
Katz,
Hydrops fetalis from B19 parvovirus infection.
1990,
Pubmed
Klingel,
Molecular pathology of inflammatory cardiomyopathy.
2004,
Pubmed
Koch,
Fifth (human parvovirus) and sixth (herpesvirus 6) diseases.
2001,
Pubmed
Kühl,
Parvovirus B19 infection mimicking acute myocardial infarction.
2003,
Pubmed
Lang,
Mechanisms and significance of cell volume regulation.
2007,
Pubmed
Lang,
Functional significance of cell volume regulatory mechanisms.
1998,
Pubmed
Lang,
Potassium channels in renal epithelial transport regulation.
1992,
Pubmed
Lehmann,
Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood.
2003,
Pubmed
Li,
Genome organization of the densovirus from Bombyx mori (BmDNV-1) and enzyme activity of its capsid.
2001,
Pubmed
Lupescu,
Phospholipase A2 activity-dependent stimulation of Ca2+ entry by human parvovirus B19 capsid protein VP1.
2006,
Pubmed
Malm,
Heart failure after parvovirus B19 infection.
1993,
Pubmed
Mia,
Downregulation of Kv1.5 K channels by the AMP-activated protein kinase.
2012,
Pubmed
,
Xenbase
Mitchell,
Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections?
2002,
Pubmed
Moffatt,
Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells.
1998,
Pubmed
Munakata,
Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection.
2005,
Pubmed
Munoz,
Up-regulation of the inwardly rectifying K⁺ channel Kir2.1 (KCNJ2) by protein kinase B (PKB/Akt) and PIKfyve.
2013,
Pubmed
,
Xenbase
Munoz,
Up-regulation of Kir2.1 (KCNJ2) by the serum & glucocorticoid inducible SGK3.
2014,
Pubmed
,
Xenbase
Nilius,
Ion channels and their functional role in vascular endothelium.
2001,
Pubmed
Oyer,
Fatal intrauterine adenoviral endomyocarditis with aortic and pulmonary valve stenosis: diagnosis by polymerase chain reaction.
2000,
Pubmed
Pakladok,
Upregulation of the Na⁺-coupled phosphate cotransporters NaPi-IIa and NaPi-IIb by B-RAF.
2014,
Pubmed
,
Xenbase
Pathare,
OSR1-sensitive renal tubular phosphate reabsorption.
2012,
Pubmed
,
Xenbase
Pattison,
Diseases caused by the human parvovirus B19.
1988,
Pubmed
Rabini,
Modifications induced by plasma from insulin-dependent diabetic patients and by lysophosphatidylcholine on human Na+,K(+)-adenosine triphosphatase.
1998,
Pubmed
Schowengerdt,
Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction.
1997,
Pubmed
Shojaiefard,
Downregulation of the creatine transporter SLC6A8 by JAK2.
2012,
Pubmed
,
Xenbase
Sokal,
Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children.
1998,
Pubmed
Sol,
Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19.
1999,
Pubmed
Telerman,
A model for tumor suppression using H-1 parvovirus.
1993,
Pubmed
Trapani,
Human parvovirus B19 infection: its relationship with systemic lupus erythematosus.
1999,
Pubmed
Tschöpe,
High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction.
2005,
Pubmed
Warsi,
Downregulation of chloride channel ClC-2 by Janus kinase 3.
2014,
Pubmed
,
Xenbase
Weigel-Kelley,
Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry.
2003,
Pubmed
Yoto,
Human parvovirus B19 infection associated with acute hepatitis.
1996,
Pubmed
Young,
Parvovirus B19.
2004,
Pubmed
Zádori,
A viral phospholipase A2 is required for parvovirus infectivity.
2001,
Pubmed
